SCHEMBL15979708

SCHEMBL15979708

Cc1csc(C(=O)CCC(=O)c2cc(Cl)cs2)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.52
GSK3B P49841 5/20 0.44
CASP3 P42574 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
KDR P35968 3/20 0.39
CCR2 P41597 2/20 0.37
ALDH1A1 P00352 2/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
MAPT P10636 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CTNNB1 P35222 1/20 0.33
WNT3A P56704 1/20 0.33
ALAD P13716 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15988713 0.89 GSK3B (0.47) DAOGSK3BALDH1A1MEN1NPC1
SCHEMBL15979699 0.89 DAO (0.63) DAOGSK3BCASP3SENP7KDR
SCHEMBL6917802 0.82 DAO (0.60) DAOGSK3BALDH1A1MEN1NPC1
SCHEMBL27577455 0.82 GSK3B (0.42) DAOGSK3BALDH1A1MEN1NPC1
SCHEMBL3867877 0.82 DAO (0.55) DAOGSK3BCASP3SENP7KDR
SCHEMBL2773258 0.82 DAO (0.55) DAOGSK3BCASP3SENP7KDR
SCHEMBL15979698 0.81 GSK3B (0.62) DAOGSK3BCASP3SENP7KDR
SCHEMBL28474265 0.80 DAO (0.57) DAOGSK3BCASP3SENP7KDR
SCHEMBL6790693 0.80 GSK3B (0.66) DAOGSK3BKDRMAPTNPSR1
SCHEMBL10513732 0.78 GSK3B (0.44) DAOGSK3BALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11673885-B2 γ-diketones as Wnt/β-catenin signaling pathway activators BIOSPLICE THERAPEUTICS, INC. (US) 2023-06-13 US disclosed
US-20180193244-A1 GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES VICKERS VENTURE FUND VI PTE. LTD. (SG) 2018-07-12 US disclosed
US-9951053-B2 γ-diketones as Wnt/β-catenin signaling pathway activators SAMUMED, LLC (US) 2018-04-24 US disclosed
US-20170260176-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS MED-PATHWAYS II LIMITED (VG) 2017-09-14 US disclosed
US-9533976-B2 γ-diketones as WNT/β-catenin signaling pathway activators SAMUMED, LLC (US) 2017-01-03 US disclosed
US-20140243349-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS VICKERS VENTURE FUND VI PTE. LTD. (SG) 2014-08-28 US disclosed
US-7902196-B2 Synthesis of avrainvillamide, strephacidin B, and analogues thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180193244-A1 GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES GLA, DGKG, DGKA DAO 239/4885GSK3B 613/4885CASP3 1584/4885
US-20170260176-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS GSK3A, GSK3B, WNT1 DAO 3651/4885GSK3B 2/4885CASP3 588/4885
US-20140243349-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS GSK3A, GSK3B, WNT1 DAO 3651/4885GSK3B 2/4885CASP3 588/4885
US-11673885-B2 γ-diketones as Wnt/β-catenin signaling pathway activators GSK3A, GSK3B, WNT1 DAO 3757/4885GSK3B 2/4885CASP3 543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.